<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511095</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-14</org_study_id>
    <nct_id>NCT00511095</nct_id>
  </id_info>
  <brief_title>Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine</brief_title>
  <official_title>An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further evaluate the safety and seroprotective immune
      response of a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, in subjects
      11-55 years old. The primary hypothesis is that HEPLISAV™ is well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of two injections of HEPLISAV™ in subjects
      11 to 55 years old. About 200 subjects will be included in the study. Once subjects have been
      consented and screened, they will receive a total of two injections over a 28-day period,
      with follow-up visits at 8, 12 and 28 weeks. Safety and tolerability will be evaluated by
      occurrence of adverse events, periodic laboratory tests, vital signs, and local/systemic
      reactogenicity.

      Comparison: This study does not include a control treatment; all subjects will receive
      treatment with HEPLISAV™.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Local and Systemic Post-injection Reaction Rates</measure>
    <time_frame>Within 7 days post-injection for post-injection reactions at Week 0 and Week 4</time_frame>
    <description>Local and Systemic post-injection reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Have a Seroprotective Immune Response (Anti-HBsAg ≥ 10 Milli-international Unit (mIU)/mL) at Weeks 4, 8, 12 and 28.</measure>
    <time_frame>Weeks 4, 8, 12 and 28</time_frame>
    <description>Seroprotective Immune Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum GMC of Anti-HBsAg Measured at Weeks 4, 8, 12, and 28</measure>
    <time_frame>Weeks 4, 8, 12, and 28</time_frame>
    <description>Measurement of Serum GMC</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HEPLISAV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV</intervention_name>
    <description>Intramuscular (IM) injections 0.5mL on Day 0 and Week 4</description>
    <arm_group_label>HEPLISAV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Women of childbearing potential must be willing to consistently use a highly effective
             method of birth control

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Any previous HBV infection

          -  Previous vaccination (1 or more doses) with any HBV vaccine

          -  Any previous autoimmune diseases

          -  Are at high risk for recent exposure to HBV, Hepatitis C Virus (HCV) or Human
             Immunodeficiency Virus (HIV)

          -  Received any blood products or antibodies within 3 months prior to study entry

          -  Ever received an injection with DNA plasmids or oligonucleotides

          -  Received any vaccines within 4 weeks prior to study entry

          -  Received any other investigational medicinal agent within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Martins, MD, DPhil</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beeghley Medical Park</name>
      <address>
        <city>Boardman</city>
        <state>Ohio</state>
        <zip>44512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Healthcare Partners</name>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance Southwestern</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Medical Associates South</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Washington Hospital Family Medicine</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dynavax.com</url>
    <description>Dynavax Webpage</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <results_first_submitted>March 1, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <disposition_first_submitted>June 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 22, 2010</disposition_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>HBV vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>Vaccine</keyword>
  <keyword>1018</keyword>
  <keyword>HBsAg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 0 and Week 4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 0 and Week 4</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Local and Systemic Post-injection Reaction Rates</title>
        <description>Local and Systemic post-injection reactions.</description>
        <time_frame>Within 7 days post-injection for post-injection reactions at Week 0 and Week 4</time_frame>
        <population>Safety Population: Subjects who received at least 1 study injection and had any post-baseline safety data</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV (Week 0)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 0</description>
          </group>
          <group group_id="O2">
            <title>HEPLISAV (Week 4)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local and Systemic Post-injection Reaction Rates</title>
          <description>Local and Systemic post-injection reactions.</description>
          <population>Safety Population: Subjects who received at least 1 study injection and had any post-baseline safety data</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Reaction: Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Reaction: Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.2"/>
                    <measurement group_id="O2" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Have a Seroprotective Immune Response (Anti-HBsAg ≥ 10 Milli-international Unit (mIU)/mL) at Weeks 4, 8, 12 and 28.</title>
        <description>Seroprotective Immune Response</description>
        <time_frame>Weeks 4, 8, 12 and 28</time_frame>
        <population>Intent-to-treat population: Enrolled subjects who received at least 1 study injection irrespective of available immune response data.</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV (Week 4)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 4</description>
          </group>
          <group group_id="O2">
            <title>HEPLISAV (Week 8)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 8</description>
          </group>
          <group group_id="O3">
            <title>HEPLISAV (Week 12)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 12</description>
          </group>
          <group group_id="O4">
            <title>HEPLISAV (Week 28)</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 28</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Have a Seroprotective Immune Response (Anti-HBsAg ≥ 10 Milli-international Unit (mIU)/mL) at Weeks 4, 8, 12 and 28.</title>
          <description>Seroprotective Immune Response</description>
          <population>Intent-to-treat population: Enrolled subjects who received at least 1 study injection irrespective of available immune response data.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="84.9"/>
                    <measurement group_id="O3" value="93.4"/>
                    <measurement group_id="O4" value="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum GMC of Anti-HBsAg Measured at Weeks 4, 8, 12, and 28</title>
        <description>Measurement of Serum GMC</description>
        <time_frame>Weeks 4, 8, 12, and 28</time_frame>
        <population>Intent-to-treat population: Enrolled subjects who received at least 1 study injection irrespective of available immune response data.
Note: &quot;Number Analyzed&quot; is the number of subjects with nonmissing concentrations at that visit.</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 0 and Week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Serum GMC of Anti-HBsAg Measured at Weeks 4, 8, 12, and 28</title>
          <description>Measurement of Serum GMC</description>
          <population>Intent-to-treat population: Enrolled subjects who received at least 1 study injection irrespective of available immune response data.
Note: &quot;Number Analyzed&quot; is the number of subjects with nonmissing concentrations at that visit.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="7.8" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="69.1" upper_limit="136.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.7" lower_limit="127.9" upper_limit="227.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349.4" lower_limit="271.8" upper_limit="449.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HEPLISAV</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV: Intramuscular (IM) injections at Week 0 and Week 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Janssen MD \ VP &amp; Chief Medical Officer</name_or_title>
      <organization>Dynavax Technologies, Inc.</organization>
      <phone>510-848-5100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

